149 related articles for article (PubMed ID: 2132196)
21. Familial aggregation of non-insulin dependent diabetes and coronary heart disease are accompanied by different effects on serum lipids, lipoproteins and apolipoproteins.
Sarlund H; Laakso M; Voutilainen E; Penttilä I; Pyörälä K
Atherosclerosis; 1991 Jan; 86(1):17-29. PubMed ID: 2064632
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein(a) concentrations in type 2 (non-insulin dependent) diabetic patients from Romania.
Dabelea D; Serban V; Băcanu GS; Deutsch G; Dan I
Rom J Intern Med; 1995; 33(1-2):85-92. PubMed ID: 8535357
[TBL] [Abstract][Full Text] [Related]
23. Sex-specific differences in blood lipids and lipid ratios in type 2 diabetic foot patients.
Yin S; Zhao P; Ai Z; Deng B; Jia W; Wang H; Zheng J
J Diabetes Investig; 2021 Dec; 12(12):2203-2211. PubMed ID: 34137504
[TBL] [Abstract][Full Text] [Related]
24. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
[TBL] [Abstract][Full Text] [Related]
25. Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels.
Cassader M; Ruiu G; Gambino R; Alemanno N; Veglia F; Pagano G
Atherosclerosis; 1993 Feb; 99(1):47-53. PubMed ID: 8461059
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein (a) levels in patients with type 1 diabetes mellitus are unrelated to metabolic control or vascular disease.
Knöbl P; Pietschmann P; Schnack C; Prager R; Schernthaner G
Wien Klin Wochenschr; 1994; 106(23):728-32. PubMed ID: 7856176
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
28. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects.
Rahmani M; Raiszadeh F; Allahverdian S; Kiaii S; Navab M; Azizi F
Atherosclerosis; 2002 Jun; 162(2):381-9. PubMed ID: 11996958
[TBL] [Abstract][Full Text] [Related]
29. Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects.
O'Neal DN; Lewicki J; Ansari MZ; Matthews PG; Best JD
Atherosclerosis; 1998 Jan; 136(1):1-8. PubMed ID: 9544725
[TBL] [Abstract][Full Text] [Related]
30. Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes.
Joven J; Vilella E; Costa B; Turner PR; Richart C; Masana L
Clin Chem; 1989 May; 35(5):813-6. PubMed ID: 2720975
[TBL] [Abstract][Full Text] [Related]
31. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM.
Abate N; Vega GL; Garg A; Grundy SM
Atherosclerosis; 1995 Nov; 118(1):111-22. PubMed ID: 8579621
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia.
Stewart MW; Laker MF; Dyer RG; Game F; Mitcheson J; Winocour PH; Alberti KG
Arterioscler Thromb; 1993 Jul; 13(7):1046-52. PubMed ID: 8318506
[TBL] [Abstract][Full Text] [Related]
33. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
34. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.
Siegel RD; Cupples A; Schaefer EJ; Wilson PW
Metabolism; 1996 Oct; 45(10):1267-72. PubMed ID: 8843183
[TBL] [Abstract][Full Text] [Related]
35. Effect of nephropathy on the composition of apolipoprotein-containing particles in NIDDM.
Nagai T; Tomizawa T; Nakajima K; Uehara Y; Mori M
J Atheroscler Thromb; 1998; 5(2):54-9. PubMed ID: 10855558
[TBL] [Abstract][Full Text] [Related]
36. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.
Nielsen FS; Voldsgaard AI; Gall MA; Rossing P; Hommel E; Andersen P; Dyerberg J; Parving HH
Diabetologia; 1993 May; 36(5):438-44. PubMed ID: 8314449
[TBL] [Abstract][Full Text] [Related]
38. HDL subparticles and coronary artery disease in NIDDM.
O'Brien T; Nguyen TT; Hallaway BJ; Hodge D; Bailey K; Kottke BA
Atherosclerosis; 1996 Apr; 121(2):285-91. PubMed ID: 9125302
[TBL] [Abstract][Full Text] [Related]
39. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.
Tan CE; Chew LS; Chio LF; Tai ES; Lim HS; Lim SC; Jayakumar L; Eng HK; Packard CJ
Diabetes Res Clin Pract; 2001 Feb; 51(2):107-14. PubMed ID: 11165690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
